Navigation Links
Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca

AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008

NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City Fire Department Emergency Medical Technician whose diabetes was allegedly caused by AstraZeneca's drug Seroquel. The plaintiff, EMT Ernest Armstead, was one of the many brave responders on the morning of September 11, 2001. He was severely injured when the World Trade Center's North Tower collapsed as he was helping victims at the foot of the buildings.

Suffering from Post-Traumatic Stress Disorder after recovery from his 9/11 physical injuries, Mr. Armstead was prescribed Seroquel, which Weitz & Luxenberg claims did not carry a warning that the powerful drug can cause diabetes. He thereafter developed the debilitating, life-long disease known as Type 2 diabetes. Mr. Armstead joins thousands of others across the country who has filed actions claiming that Seroquel caused them to develop diabetes and that AstraZeneca hid its knowledge of this risk from the FDA, doctors and patients.

In a letter dated November 16, 2006, the Department of Health and Human Services of the Food and Drug Administration cited violations of the Federal Food, Drug, and Cosmetic Act in connection with AstraZeneca's use of promotional material deemed by the FDA to be "false or misleading because it minimizes the risk of hyperglycemia and diabetes mellitus" and which "raises significant public health and safety concerns through its minimization of the risks associated with Seroquel."

A deposition of AstraZeneca's Chief Executive Officer, David Brennan, about his company's alleged undisclosed knowledge regarding the dangerous side effect of diabetes, is being taken this Friday, June 20th in London, England at the law offices of Baker Botts, a U.S. firm defending the company. Lawyers from three of the lead plaintiffs' counsel in the litigation (Blizzard, McCarthy & Nabers; Weitz & Luxenberg; and Bailey, Perrin, Bailey) will be conducting the deposition.

About Weitz & Luxenberg P.C.: Weitz & Luxenberg, founded in 1986, is one of the leading plaintiffs' litigation law firms in America. The firm has played leading roles in national and local litigations involving asbestos/mesothelioma, DES, silicone breast implants, defective medicines and medical devices, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE among other toxins. The firm recently secured a landmark MTBE settlement against some of the country's biggest oil companies, which have agreed to pay $423 million in a suit involving the contamination of 153 public water systems nationally.

SOURCE Weitz & Luxenberg, PC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
2. Jazz Pharmaceuticals Files Form S-3 Registration Statements
3. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. Immunosyn Corporation Files 10-Q
6. Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
7. Benda Pharmaceutical Files Amendment To Form S-1
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Vion Pharmaceuticals Files Plan With Nasdaq
10. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a ... its first quarter ended September 30, 2015. ... of fiscal 2016 grew 66 percent over the comparable quarter last ... fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... for the first quarter of fiscal 2016 grew 39 percent over ...
Breaking Biology News(10 mins):